Date: 2014-09-15
Type of information: Collaboration agreement
Compound: cell-based high throughput screening assay, screening of compound libraries
Company: Evotec (Germany) the Jain Foundation (USA - WN)
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
Type agreement: collaboration R&D
Action mechanism:
Disease: dysferlinopathy
Details: * On August 21, 2013, Evotec and the Jain Foundation have extended and expanded their research collaboration leveraging Evotec’s assay development and screening capabilities to support the Jain Foundation’s goals of understanding and curing dysferlinopathy. In 2012, Evotec and the Jain foundation initiated a research project to develop a cell-based high throughput screening assay using dysferlin deficient cells. The aim of this project is to develop a simple test for the well-being of a muscle cell in the absence of dysferlin so that compounds that improve the well-being of dysferlin deficient muscle cells can be identified.
Financial terms: No financial details were disclosed.
Latest news: * On September 15, 2014, Evotec and the Jain Foundation announced that they have further extended and expanded the collaboration first signed in 2012 and extended last year. This next phase of collaboration includes the screening of compound libraries in multiple assay formats to further support the Jain Foundation’s goals of understanding and curing dysferlinopathies, a group of inherited skeletal muscular dystrophy diseases. This marks a major milestone in the efforts of the Jain Foundation to identify therapeutics which can counteract the phenotypes of dysferlin deficiency
